Morphotek® Announces Antibody Development Agreement with the University of Pennsylvania
News Dec 23, 2008
Morphotek®, Inc., a subsidiary of Eisai Corporation of North America, announced today that it has signed a Sponsored Research Agreement with The University of Pennsylvania to fund research for the development of therapeutic antibody candidates targeting an antigen associated with hypoxic regions in tumors. Hypoxia is a condition in which suboptimal oxygen concentrations exist in tissues.
“We are very interested in and looking forward to this collaboration, as targeting the hypoxic tumor microenvironment is a high priority in our ongoing efforts to develop more effective cancer therapies," said Dr. Wafik S. El-Deiry, Professor of Medicine, Genetics and Pharmacology at the University of Pennsylvania School of Medicine and Co-Program Leader of the Radiation Biology & Imaging Program at the Abramson Comprehensive Cancer Center, and Associate Director for Physician-Scientist Training in Hematology/Oncology at University of Pennsylvania.
“We believe this relationship may lead to a deeper understanding of hypoxia pathways and their role in cancers, and may ultimately lead to the development of therapeutic monoclonal antibodies that target antigens required for tumor cells to survive in hypoxic regions,” Dr. Wafik added.
“Morphotek continues to expand its oncology product pipeline through the addition of promising new targets and antibodies, and through the development of its therapeutic antibody candidates,” stated Nicholas C. Nicolaides, Ph.D., President and CEO of Morphotek.
“This collaboration builds upon our existing relationships with leading researchers at the University of Pennsylvania for possible advancement of therapeutic monoclonal antibody candidates into clinical trials. Dr. Wafik El-Deiry and his team bring significant expertise to our program in the area of tumor hypoxia, and we are very excited to be working together with his group,” Nicolaides said.
Computation and Chemistry Combine to Create World-First Auxetic ProteinNews
A team of chemists at the University of California, San Diego (UCSD) has now designed a two-dimensional protein crystal that toggles between states of varying porosity and density. This is a first in biomolecular design that combined experimental studies with computation done on supercomputers. The research, published in April 2018 in Nature Chemistry, could help create new materials for renewable energy, medicine, water purification, and more.
Fructose Formula Poses Risk to Babies With Metabolic DisorderNews
Babies with inherited intolerance of fructose face a risk of acute liver failure if they are fed certain widely available formulas containing fructose, pediatricians and geneticists are warning. Baby formula manufacturers should remove fructose or sucrose, or explicitly label their products to allow parents to avoid those sweeteners if necessary, the doctors say.
Plant Peptide Gives Relief From Salty StressNews
Researchers have discovered a hormone-like peptide in plants that helps increase their tolerance to excessive salt. They found several genes that can increase salinity tolerance, the most effective being a small gene that codes for the peptide AT13READ MORE